bpc 157 venous insufficiency Frontiers Chronic Deep Vein Thrombosis: Pentadecapeptide
Description
2011 Feb 8;3:25-35
There is no need to be re-tested
Delivery Viability We evaluate the formulation science to determine if oral and nasal applications provide meaningful systemic or localized bioavailability
The documented research protocol is once daily: 150 mcg from the 10 mg vial, or 2.5 mg from the 50 mg vial
